Immunostimulating vector system
Provided is a novel vector for immunostimulation and methods of using same in immunotherapy, in particular cancer immunotherapy. The novel vector comprises nucleic acid sequences encoding 4-1BB ligand (4-1BBL, CD137 ligand), single chain IL-12 (sc IL-12) and IL-2, wherein the vector provides for an increased expression of 4-1BBL as compared to the expression levels of sc IL-12 and IL-2. Specifically, the nucleic acid sequences encoding 4-1BBL, sc IL-12 and IL-2 are organized in the vector in 5′ to 3′ orientation in a sequential order 1, 2, 3, with the proviso that the gene encoding sc IL-12 is not at position 1. Embodiments of the present disclosure include virus particles comprising the novel vector as well as cancer or immune cells transduced or transfected with the novel vector.
1. A vector comprising the nucleotide sequence of SEQ ID NO:12, which comprises nucleic acid sequences encoding 4 1BB ligand (4-1BBL), single chain IL-12 (scIL-12), and IL-2.
2. The vector of claim 1 , wherein the vector is any one of an adenoviral vector, an adeno-associated virus vector, a lentiviral vector, a herpes simplex virus vector, a pox virus vector, an RNA vector, a plasmid vector, a nanoparticle vector, and naked DNA.
3. A cancer cell or an immune cell, transduced or transfected with the vector of claim 1 .
4. A medicament comprising the vector of claim 1 .